Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Real-World Clinical Outcomes in Patients with Relapse and Refractory Multiple Myeloma Received VTD-PACE Treatment in the Era of Monoclonal Antibody

Moe Yogo, Taku Kikuchi, Nobuhiro Tsukada, Kodai Kunisada, Yuki Okda, Kota Sato, Mizuki Ogura, Tomomi Takei, Yu ABE, Kenshi Suzuki, Tadao Ishida

Blood (2023) 142 (Supplement 1): 6625.

https://doi.org/10.1182/blood-2023-174725

Published: 2023

Journal Articles

Normal B Cell-Derived iPSCs Capable of Inducing RAS Mutants and Aid to Explore Myeloma-Initiating Cells

Ken-ichi Kudo, Naohiro Tsuyama, Misaki Takahashi Sugai, Yusuke Azami, Miwa Fukami, Yu Abe, Akinobu Ota, Karnan Sivasundaram, Moe Muramatsu, Megumi Sasatani, Yuko Hashimoto, Shigehira Saji, Kenji Kamiya, Ichiro Hanamura, Takayuki Ikezoe, Masafumi Onodera, Akira Sakai

Blood (2021) 138 (Supplement 1): 4711.

https://doi.org/10.1182/blood-2021-149108

Published: 2021

Journal Articles

Efficacy of Modified Vrd-Lite for Transplant Ineligible Multiple Myeloma

Mizuki Ogura, MDPhD, Tadao Ishida, MDPhD, Moe Nomura, Hirofumi Irita, Junichiro Nashimoto, Kota Sato, MDPhD, Kanji Miyazaki, MDPhD, Yu Abe, MD, Nobuhiro Tsukada, MDPhD, Kenshi Suzuki, MD PhD

Blood (2020) 136 (Supplement 1): 4.

https://doi.org/10.1182/blood-2020-143459

Published: 2020

Journal Articles

The Clinical Features of Multiple Myeloma with AL Amyloidosis

Junichiro Nashimoto, Moe Nomura, Hirofumi Irita, Kota Sato, MDPhD, Kanji Miyazaki, MDPhD, Mizuki Ogura, MDPhD, Yu Abe, MD, Nobuhiro Tsukada, MDPhD, Tadao Ishida, MDPhD, Kenshi Suzuki, MD PhD

Blood (2020) 136 (Supplement 1): 10.

https://doi.org/10.1182/blood-2020-142362

Published: 2020

Journal Articles

Chromosomal Translocation t(11;14) Induced By the Cre-Loxp System in Normal B Cell-Derived Ips Cells for the Study of Myeloma-Initiating Cells

Misaki Sugai, BS, Naohiro Tsuyama, PhD, Yu Abe, PhD, Yusuke Azami, MD, Kenichi Kudo, PhD, Akinobu Ota, PhD, Sivasundaram Karnan, PhD, Moe Muramatsu, BS, Tomonari Shigemura, MD PhD, Megumi Sasatani, PhD, Yuko Hashimoto, MD PhD, Kenji Kamiya, MD PhD, Ichiro Hanamura, MD PhD, Takayuki Ikezoe, MD PhD, Masafumi Onodera, MD PhD, Akira Sakai, MD PhD

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-134572

Published: 2020

Journal Articles

Introduction of Chromosomal Translocation t(11; 14) and a p53 Deletion into Normal B Cell-Derived iPSCs to Elucidate the Cellular Origin of Myeloma Cells

Aki Yanagi, MS, Naohiro Tsuyama, PhD, Misaki Sugai, BS, Yu Abe, PhD, Yusuke Azami, MD, Yukari Yanai, MS, Akinobu Ota, PhD, Karnan Sivasundaram, PhD, Moe Muramatsu, BS, Tomonari Shigemura, MD PhD, Megumi Sasatani, PhD, Yuko Hashimoto, MD PhD, Kenji Kamiya, MD PhD, Ichiro Hanamura, MD PhD, Takayuki Ikezoe, MD PhD, Masafumi Onodera, MD PhD, Akira Sakai, MD PhD

Blood (2019) 134 (Supplement_1): 3057.

https://doi.org/10.1182/blood-2019-122344

Published: 2019

Journal Articles

Attempt to Prove the Existence of Abnormal B Lymphocyte As Myeloma-Initiating Cells from B Cell-Derived Induced Pluripotent Stem Cells

Aki Yanagi, MS, Naohiro Tsuyama, PhD, Yukari Yanai, MS, Yu Abe, PhD, Misaki Sugai, BS, Akinobu Ota, PhD, Karnan Sivasundaram, PhD, Tomonari Shigemura, MD PhD, Megumi Sasatani, PhD, Kenji Kamiya, MD PhD, Ichiro Hanamura, MD PhD, Takayuki Ikezoe, MD PhD, Masafumi Onodera, MD PhD, Akira Sakai, MD PhD

Blood (2018) 132 (Supplement 1): 1896.

https://doi.org/10.1182/blood-2018-99-112759

Published: 2018

Journal Articles

Retrospective Analysis of the Efficacy and Safety of Modified Bortezomib-Lenalidomide-Dexamethasonelite (modified RVD-lite) Therapy for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma

Kiyoshi Okazuka, MD, Tadao Ishida, MDPhD, Junichiro Nashimoto, MD, Takao Yogo, MD, Kanji Miyazaki, MD, Kota Sato, MDPhD, Yui Uto, MD PhD, Mizuki Ogura, MDPhD, Yumiko Yoshiki, MDPhD, Yu ABE, MD, Nobuhiro Tsukada, MDPhD, Kenshi Suzuki, MD PhD

Blood (2018) 132 (Supplement 1): 1961.

https://doi.org/10.1182/blood-2018-99-112294

Published: 2018

Journal Articles

Phase II Study of the Bortezomib-Melphalan-Prednisolone Induction Therapy Followed By Lenalidomide-Plus-Dexamethasone Consolidation and Lenalidomide Maintenance in Non-Transplant Eligible Patients with Newly Diagnosed Symptomatic Multiple Myeloma (CANDLE trial)

Blood (2017) 130 (Supplement 1): 3121.

https://doi.org/10.1182/blood.V130.Suppl_1.3121.3121

Published: 2017

Journal Articles

Retrospective Analysis of High-Dose Melphalan and Autologous Stem Cell Transplantation for Systemic Light-Chain Amyloidosis: A Single Center 63 Cases

Kiyoshi Okazuka, MD, Nobuhiro Tsukada, Kota Sato, MD, Kanji Miyazaki, Yumiko Yoshiki, Yu Abe, MD, Tadao Ishida, MD, Kenshi Suzuki

Blood (2017) 130 (Supplement 1): 4542.

https://doi.org/10.1182/blood.V130.Suppl_1.4542.4542

Published: 2017

Journal Articles

B Cell-Derived Induced Pluripotent Stem Cells Are Useful for Determining the Cellular Origin of Abnormal B Cells in Multiple Myeloma

Aki Yanagi, Fumihiko Kawamura, MS, Makoto Inaki, PhD, Atsushi Katafuchi, PhD, Yukari Yanai, MS, Yu Abe, MD, Naohiro Tsuyama, PhD, Misaki Sugai, BS, Mitsunori Higuchi, MD PhD, Satoshi Muto, MD PhD, Takumi Yamaura, MD, Hiroyuki Suzuki, MD PhD, Hideyoshi Noji, MD PhD, Shinichi Suzuki, MD PhD, Yoshida A Mitsuaki, PhD, Megumi Sasatani, PhD, Kenji Kamiya, MD PhD, Masafumi Onodera, MD PhD, Akira Sakai, MDPhD

Blood (2017) 130 (Supplement 1): 1808.

https://doi.org/10.1182/blood.V130.Suppl_1.1808.1808

Published: 2017

Journal Articles

Establishment of Induced Pluripotent Stem Cells from Lymph Node B Cells and Induction of Aid Expression in Their Differentiation into Hematopoietic Stem Cells

Fumihiko Kawamura, MS, Inaki Makoto, PhD, Atsushi Katafuchi, PhD, Yu Abe, MS, Naohiro Tsuyama, PhD, Yumiko Kurosu, BS, Aki Yanagi, MS, Mitsunori Higuchi, MD PhD, Satoshi Muto, MD PhD, Takumi Yamamura, MD, Hiroyuki Suzuki, MD PhD, Hideyoshi Noji, MD PhD, Shinichi Suzuki, MD PhD, Mitsuaki A Yoshida, PhD, Megumi Sasatani, PhD, Kenji Kamiya, MD PhD, Masafumi Onodera, MD PhD, Akira Sakai, MD PhD

Blood (2016) 128 (22): 5049.

https://doi.org/10.1182/blood.V128.22.5049.5049

Published: 2016

Journal Articles

Difference of Treatment Outcomes in AL Amyloidosis and Multiple Myeloma with / without Translocation (11;14)

Kenshi Suzuki, Miho Kasuga, trainee, Kanji Miyazaki, MD, Sohsuke Meshitsuka, MD, Yu ABE, MD, Yumiko Yoshiki, MD PhD, Nobuhiro Tsukada, MD PhD

Blood (2015) 126 (23): 4224.

https://doi.org/10.1182/blood.V126.23.4224.4224

Published: 2015

Journal Articles

Impact Of Novel Agents To The Additional-Chromosomal Abnormalities In Patients With Multiple Myeloma

Kenshi Suzuki, MD, PhD, Yu Abe, Kanji Miyazaki, Rieko Sekine, MD, PhD, Nobuhiro Tsukada, MD, PhD, Yutaka Hattori, MD, PhD, Airi Hamano, Sumito Shingaki

Blood (2013) 122 (21): 3225.

https://doi.org/10.1182/blood.V122.21.3225.3225

Published: 2013

Journal Articles

Discovery Research On the Effects of Continuous Administration of Bortezomib Maintenance Therapy to Treat Patients with Relapsed and Refractory Multiple Myeloma - Analysis of Background Factors That Affect the Continuity of Therapy-

Kenshi Suzuki, MD, PhD, Nobuhiro Tsukada, MD, PhD, Yu Abe, MD, Rieko Sekine, MD, PhD, Yasunori Nakagawa, MD, PhD

Blood (2012) 120 (21): 1866.

https://doi.org/10.1182/blood.V120.21.1866.1866

Published: 2012

Journal Articles

Sucessful Management of Pregnancy and Remission-Induction of a Patient with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) by Means of Imatinib Mesilate and HyperCVAD.

Toshiya Suzuki, MD, Yu Abe, MD, Yuki Mori, MD, Yasunori Nakagawa, MD, Keiko Saito, MD, Yoko Matsumoto, MD, Akito Miyauchi, MD, Mitsuhiro Sugimoto, MD, Kenshi Suzuki

Blood (2007) 110 (11): 4327.

https://doi.org/10.1182/blood.V110.11.4327.4327

Published: 2007

NARROW

Real-World Clinical Outcomes in Patients with Relapse and Refractory Multiple Myeloma Received VTD-PACE Treatment in the Era of Monoclonal Antibody

Normal B Cell-Derived iPSCs Capable of Inducing RAS Mutants and Aid to Explore Myeloma-Initiating Cells

Efficacy of Modified Vrd-Lite for Transplant Ineligible Multiple Myeloma

The Clinical Features of Multiple Myeloma with AL Amyloidosis

Chromosomal Translocation t(11;14) Induced By the Cre-Loxp System in Normal B Cell-Derived Ips Cells for the Study of Myeloma-Initiating Cells

Introduction of Chromosomal Translocation t(11; 14) and a p53 Deletion into Normal B Cell-Derived iPSCs to Elucidate the Cellular Origin of Myeloma Cells

Attempt to Prove the Existence of Abnormal B Lymphocyte As Myeloma-Initiating Cells from B Cell-Derived Induced Pluripotent Stem Cells

Retrospective Analysis of the Efficacy and Safety of Modified Bortezomib-Lenalidomide-Dexamethasonelite (modified RVD-lite) Therapy for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma

Phase II Study of the Bortezomib-Melphalan-Prednisolone Induction Therapy Followed By Lenalidomide-Plus-Dexamethasone Consolidation and Lenalidomide Maintenance in Non-Transplant Eligible Patients with Newly Diagnosed Symptomatic Multiple Myeloma (CANDLE trial)

Retrospective Analysis of High-Dose Melphalan and Autologous Stem Cell Transplantation for Systemic Light-Chain Amyloidosis: A Single Center 63 Cases

B Cell-Derived Induced Pluripotent Stem Cells Are Useful for Determining the Cellular Origin of Abnormal B Cells in Multiple Myeloma

Establishment of Induced Pluripotent Stem Cells from Lymph Node B Cells and Induction of Aid Expression in Their Differentiation into Hematopoietic Stem Cells

Difference of Treatment Outcomes in AL Amyloidosis and Multiple Myeloma with / without Translocation (11;14)

Impact Of Novel Agents To The Additional-Chromosomal Abnormalities In Patients With Multiple Myeloma

Discovery Research On the Effects of Continuous Administration of Bortezomib Maintenance Therapy to Treat Patients with Relapsed and Refractory Multiple Myeloma - Analysis of Background Factors That Affect the Continuity of Therapy-

Sucessful Management of Pregnancy and Remission-Induction of a Patient with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) by Means of Imatinib Mesilate and HyperCVAD.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only